Tamsulosin Monotherapy Is Effective in Reducing Ureteral Stentrelated Symptoms:A Meta-analysis of Randomized Controlled Studies  

作　　者：Yong-bo CHEN Liang GAO Qing JIANG Ke RAN Run-tian LUO 

机构地区：[1]Department of Urology,the Second Affiliated Hospital of Chongqing Medical University,Chongqing 400010,China

出　　处：《Current Medical Science》2019年第5期707-718,共12页当代医学科学（英文）

摘　　要：This study aimed to evaluate the effectiveness of tamsulosin monotherapy for the treatment of ureteral stent-related symptoms(SRSs)and compare it with that of solifenacin monotherapy and combined therapy of tamsulosin and silifenacin.Randomized controlled trials(RCTs),which evaluated the effectiveness of tamsulosin for the treatment of SRSs,were searched from the databases PubMed,EMBASE and the Cochrane Library published up to November 2018.Eight RCTs involving 1087 participants were finally included in this meta-analysis.The results showed that tamsulosin monotherapy could significantly decrease the urinary symptoms[mean difference(MD)—7.56,95%confidence interval(CI)(-11.47,-3.65),P=0.0001]and body pain[MD-5.25,95%CI(-8.03,-2.46),P=0.0002],and improve the sexual performance[MD-1.06,95%CI(-1.89,-0.24),P=0.01]compared with the control group.Moreover,there was no significant difference between tamsulosin monotherapy and solifenacin monotherapy in all outcomes except for significantly better sexual performance in solifenacin group[MD 0.29,95%CI(0.06,0.51),P=0.01].In addition,the effectiveness of combined therapy of tamsulosin and solifenacin was not superior to that of tamsulosin monotherapy.Our study demonstrated that tamsulosin monotherapy was effective for the treatment of patients with SRSs;evident superiority could not be found for therapy of tamsulosin and solifenacin combined.

关 键 词：TAMSULOSIN SOLIFENACIN ureteral stent-related SYMPTOMS META-ANALYSIS 

分 类 号：R98[医药卫生—药品]